Agilent splits up to create two separate businesses

Agilent is splitting into two companies
Agilent is splitting into two companies

Related tags Molecular biology Chromatography

Agilent Technologies has officially separated its biopharma service offerings from its electric measurement group to create two separate companies, the life science portion of which is expected to bring in about $3.9B in FY2013.

The plan to separate into two publicly traded companies is based on the idea of increasing management’s focus on the distinct businesses and to devote more “resources to the higher-growth LDA [life sciences, diagnostics and applied markets] business​,” according to an SEC filing​ from Thursday.

The new Santa Clara, California-based life sciences portion of Agilent will include about 11,500 employees, while the electronic measurement company will be based in Santa Rosa, California and include about 9,500 employees.

Bill Sullivan will remain president and CEO of Agilent, while Didier Hirsch will continues as CFO, though the electronic measurement company will see new management.

Agilent’s life sciences division will continue to offer biopharma companies services in:

  • Liquid and gas chromatography, including reversed phase, ion exchange and size exclusion, as well as evaporative light scattering;
  • Mass spectrometry; and
  • Spectroscopy.

Agilent also offers tools to help biopharma companies purify target proteins, quantitate them, and supports enzymatic reactions. But Agilent spokesman Eric Endicott told us that biopharma "is not a focus​" of either of the two companies.

Related news

Show more

Related products

show more

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Riding the mRNA Highway

Riding the mRNA Highway

Content provided by Thermo Fisher Scientific - Biosciences | 15-May-2023 | White Paper

Learn more about process development and manufacturing in the mRNA space to enable successful scale-ups of mRNA production for therapeutic applications.

Related suppliers

Follow us


View more